Dr. Krishnapada Baidya,
BACKGROUND Central serous chorioretinopathy (CSCR) is the fourth most common retinopathy after age-related macular degeneration, diabetic retinopathy and branch retinal vein occlusion. Chronic Central Serous Chorioretinopathy is defined as persistence of sub-retinal fluid on Ocular Coherence Tomography beyond 3 months of onset of the disease. In the current study, we evaluated the efficacy of eplerenone in patients of chronic serous chorioretinopathy (CSCR). METHODS It is a randomized double blind study of sixty-eight eyes of sixty patients who were randomized into two groups. Thirty-five eyes of thirty patients in the treatment group (Group A), received 50 mg eplerenone daily for 3 months and thirty-three eyes of thirty patients in the control group (Group B) received one capsule of placebo drug (glucose powder) each day for the same duration. Visual acuity (VA), maximum height of sub-retinal fluid (SRF) and contrast sensitivity (CS) were studied at baseline and monthly thereafter for 6 months after initiation of therapy. RESULTS Better improvement of VA, reduction of SRF and improvement of CS were observed in the treatment group as compared to placebo. t-Test showed that there was significant difference in mean CS of the two groups at 6 months (p= 0.0459) and it also showed that there was significant difference in mean SRF of the two groups at the end of 6 months (p= 0.0491). CONCLUSIONS Eplerenone could be beneficial as an alternate mode of therapy in the treatment of chronic CSCR.
